Carregant...
Targeting EPO and EPO RECEPTOR PATHWAYS in Anemia and Dysregulated Erythropoiesis
INTRODUCTION: Recombinant human erythropoietin (rhEPO) is a first-line therapeutic for the anemia of chronic kidney disease, cancer chemotherapy, AIDS (Zidovudine therapy) and lower-risk myelodysplastic syndrome. However, rhEPO frequently elevates hypertension, is costly and may affect cancer progre...
Guardat en:
| Publicat a: | Expert Opin Ther Targets |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4829957/ https://ncbi.nlm.nih.gov/pubmed/26419263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14728222.2016.1090975 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|